Key result
Atorvastatin reduced thrombotic risk assessed by peak thrombin generation compared to control in diabetic patients without previous cardiovascular events, whereas aspirin had no effect.
Why the study?
Does aspirin or atorvastatin reduce thrombin generation in patients with type 2 diabetes without previous cardiovascular events?
RCT (n=30)
Open-label, blinded to events evaluation (PROBE)
Random allocation sequence generated by computer
Yes
Does aspirin or atorvastatin reduce thrombin generation in patients with type 2 diabetes without previous cardiovascular events?
Answers are grounded in this paper and cite their sources.
In patients with type 2 diabetes without previous cardiovascular events, atorvastatin but not aspirin significantly reduced thrombotic risk as assessed by thrombin generation.
BACKGROUND: The systematic use of aspirin and statins in patients with diabetes and no previous cardiovascular events is controversial. We sought to assess the effects of aspirin and statins on the thrombotic risk assessed by thrombin generation (TG) among patients with type II diabetes mellitus and no previous cardiovascular events. METHODOLOGY/PRINCIPAL FINDINGS: Prospective, randomized, open, blinded to events evaluation, controlled, 2×2 factorial clinical trial including 30 patients randomly allocated to aspirin 100 mg/d, atorvastatin 40 mg/d, both or none. Outcome measurements included changes in TG levels after treatment (8 to 10 weeks), assessed by a calibrated automated thrombogram. At baseline all groups had similar clinical and biochemical profiles, including TG levels. There was no interaction between aspirin and atorvastatin. Atorvastatin significantly reduced TG measured as peak TG with saline (85.09±55.34 nmol vs 153.26±75.55 nmol for atorvastatin and control groups, respectively; p = 0.018). On the other hand, aspirin had no effect on TG (121.51±81.83 nmol vs 116.85±67.66 nmol, for aspirin and control groups, respectively; p = 0.716). The effects of treatments on measurements of TG using other agonists were consistent. CONCLUSIONS/SIGNIFICANCE: While waiting for data from ongoing large clinical randomized trials to definitively outline the role of aspirin in primary prevention, our study shows that among diabetic patients without previous vascular events, statins but not aspirin reduce thrombotic risk assessed by TG. TRIAL REGISTRATION: ClinicalTrials.gov NCT00793754.
No takes yet. Share an insight, caveat, or question.
Macchia et al. (2012) conducted an RCT in Type 2 diabetes mellitus without previous cardiovascular events (n=30). Atorvastatin vs. No atorvastatin was evaluated on Peak thrombin generation (PTG) with saline as agonist at the end of follow-up (p=0.018). Atorvastatin reduced thrombotic risk assessed by peak thrombin generation compared to control in diabetic patients without previous cardiovascular events, whereas aspirin had no effect.
Synapse has enriched 10 related papers. Consider them for comparative context: